39. FACTORS ASSOCIATED WITH PLASMA PCT AND CRP OF INPATIENTS WITH ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Main Article Content
Abstract
Objective: To investigate factors associated with plasma Procalcitonin (PCT) and C-reactive protein (CRP) of inpatients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) at the National Lung Hospital.
Subject and method: A cross-sectional study was conducted on 200 patients diagnosed with AECOPD and admitted to the National Lung Hospital from November 2023 to May 2024. Clinical factors, Anthonisen classification, GOLD 2023 stages, and biomarkers (PCT, CRP, and white blood cell counts) were evaluated.
Results: Most patients were male (91.5%) and aged 60-79 (76.9%), with 64.0% having ≥2 hospital admissions/year and 76.0% still smoking. COPD duration of 5-10 years accounted for 49.0%, with an average hospital stay of 13.24 ± 9.08 days. Plasma CRP and PCT levels were highest in Anthonisen I and GOLD 4 at admission and lowest in Anthonisen III and GOLD 1 before discharge (p < 0.01). CRP showed a positive correlation with PCT (r = 0.192, p < 0.01) and white blood cell count (r = 0.210, p < 0.01).
Conclusion: CRP and PCT are reliable biomarkers reflecting disease severity and systemic inflammation in AECOPD patients. This study provides essential evidence to support the optimization of diagnosis and management of AECOPD.
Article Details
Keywords
acute exacerbations of chronic obstructive pulmonary disease (AECOPD), Procalcitonin (PCT) and C-reactive protein (CRP), associated factor
References
[2] Huỳnh Đình Nghĩa (2019), "Nghiên cứu nồng độ Procalcitonin huyết thanh ở bệnh nhân nam đợt cấp bệnh phổi tắc nghẽn mạn tính có hứt thuốc lá ", Tạp chí Y Dược học Cần Thơ. 7, p. 22-25.
[3] Cung Văn Tấn (2019), Nghiên cứu đặc điểm lâm sàng, cận lâm sàng, vi khuẩn gây bệnh và kết quả điều trị viêm phổi cộng đồng ở bệnh nhân bệnh phổi tắc nghẽn mạn tính tại Bệnh viện Phổi Trung ương Luận văn Bác sĩ chuyên khoa II, Đại học Y Hà Nội.
[4] Alvar Agustí , et al. (2023), "Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary", European Respiratory Journal. 61(4).
[5] Anna Maria Azzini , et al.. (2020), "A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the evidence based laboratory medicine", Annals of translational medicine. 8(9).
[6] Mona Bafadhel , et al. (2011), "Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD", Chest. 139(6), p. 1410-1418.
[7] Leoardo M Fabbri, SS Hurd (2003), "Global strategy for the diagnosis, management and prevention of COPD: 2003 update", European Respiratory Journal. 22(1), p. 1-1.
[8] Prem Parkash Gupta và Dipti Agarwal (2006), "Chronic obstructive pulmonary disease and peripheral neuropathy", Lung India. 23(1), p. 25-33.
[9] Vandack Nobre , et al. (2008), "Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial", American journal of respiratory critical care medicine. 177(5), p. 498-505.
[10] Yajun Song , et al. (2017), "The clinical study of serum hs-CRP, TNF-α, PCT and IL-6 in patients with acute exacerbation of chronic obstructive pulmonary disease", Int J Clin Exp Med. 10(9), p. 13550-6.
[11] Claus F Vogelmeier , et al. (2017), "Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary", American journal of respiratory critical care medicine. 195(5), p. 557-582.
[12] Jiarui Zhang , et al. (2024), "A simple clinical risk score (ABCDMP) for predicting mortality in patients with AECOPD and cardiovascular diseases", Respiratory Research. 25(1), p. 89.